Zobrazeno 1 - 10
of 13
pro vyhledávání: '"N. R. Hartman"'
Autor:
R F Struck, Eric K. Rowinsky, K Bowling, Louise B. Grochow, N R Hartman, Seamus O'Reilly, T L Chen, Ross C. Donehower
Publikováno v:
Journal of Clinical Oncology. 15:1974-1984
PURPOSE To determine the maximum-tolerated dose (MTD), principal toxicities, and pharmacologic behavior of penclomedine, a novel alkylating agent. PATIENTS AND METHODS Penclomedine (45 to 550 mg/ m2/d every 3 weeks) was administered as a 1- or 3-hour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f2f9390d57ad6dc94868a396aa4441
https://doi.org/10.1200/jco.1997.15.5.1974
https://doi.org/10.1200/jco.1997.15.5.1974
Autor:
Hiroaki Mitsuya, Samuel Broder, D. G. Johns, R. Yarchoan, Pim Brouwers, N. R. Hartman, James M. Pluda, Kathy Wyvill, Rose V. Thomas
Publikováno v:
The Lancet. 336:526-529
To evaluate the long-term toxicity and activity profile of 2',3'-dideoxyinosine (ddl), a potent inhibitor of human immunodeficiency virus (HIV) replication, in vitro. 58 patients with AIDS or AIDS-related complex were studied with additional referenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2258178776b50961394b653bc236c9
https://doi.org/10.1016/0140-6736(90)92085-v
https://doi.org/10.1016/0140-6736(90)92085-v
Publikováno v:
British journal of clinical pharmacology. 48(5)
Our objective was to elucidate further the underlying mechanism responsible for therapeutic failures observed with concomitant administration of the oral contraceptive 17alpha-ethinyloestradiol (EE2 ) and rifampicin.We investigated both oxidative and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a7b9e794376e6a3d301efd92cec8250
https://pubmed.ncbi.nlm.nih.gov/10594476
https://pubmed.ncbi.nlm.nih.gov/10594476
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 26(6)
Penclomedine is a multi-chlorinated alpha-picoline derivative that has demonstrated activity in several murine breast cancer models and is currently in clinical testing for use against solid tumors. This study evaluates the metabolism of penclomedine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b22d460c8448624e3b6738ce64750841
https://pubmed.ncbi.nlm.nih.gov/9616185
https://pubmed.ncbi.nlm.nih.gov/9616185
Autor:
W R, Waud, A, Tiwari, S M, Schmid, T W, Shih, J M, Strong, N R, Hartman, S, O'Reilly, R F, Struck
Publikováno v:
Cancer research. 57(5)
Penclomedine [3,5-dichloro-4,6-dimethoxy-2-(trichloromethyl)pyridine], an antitumor agent, is currently in Phase I clinical trials and is believed to be a prodrug. In these studies, cerebellar effects have been dose limiting. Previous studies identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab7dca5383d055e45d519b94a98582ca
https://pubmed.ncbi.nlm.nih.gov/9041177
https://pubmed.ncbi.nlm.nih.gov/9041177
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(6)
Penclomedine is a multichlorinated alpha-picoline derivative which has shown prominent activity in murine breast cancer models and is currently undergoing clinical development. Previous in vitro research has identified several penclomedine metabolite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ed896aecb964dabd46843f3d593d6ca
https://pubmed.ncbi.nlm.nih.gov/9816256
https://pubmed.ncbi.nlm.nih.gov/9816256
Autor:
S, O'Reilly, N R, Hartman, S A, Grossman, J M, Strong, R F, Struck, S, Eller, G J, Lesser, R C, Donehower, E K, Rowinsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(3)
Penclomedine, a lipophilic alpha-picoline derivative, is undergoing clinical development presently because of its pronounced antitumor activity against intracerebral (i.c.) tumor xenografts. Penclomedine may be metabolized in vivo to a more potent co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7bfcc8f715987f0d88ccd934b68e3bdc
https://pubmed.ncbi.nlm.nih.gov/9816201
https://pubmed.ncbi.nlm.nih.gov/9816201
Autor:
G, Ahluwalia, D A, Cooney, N R, Hartman, H, Mitsuya, R, Yarchoan, A, Fridland, S, Broder, D G, Johns
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 21(2)
The rates of accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate (ddATP) have been examined after incubation with the anti-human immunodeficiency virus (HIV) agents 2',3'-dideoxyinosine (ddIno) and 2',3'-dideoxyadenosine (ddAdo) in human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d45f1bb12f421853b366d5693e096a77
https://pubmed.ncbi.nlm.nih.gov/8097711
https://pubmed.ncbi.nlm.nih.gov/8097711
Publikováno v:
Molecular pharmacology. 42(3)
2',3'-Dideoxyguanosine (ddGuo) is a selective inhibitor of the replication of human immunodeficiency virus in vitro and the most active antihepadnavirus nucleoside analog known in vitro and in vivo, in a Peking duck model. However, the exact route by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::10716d71fee33b71140cf0d4c5a347e0
https://pubmed.ncbi.nlm.nih.gov/1328848
https://pubmed.ncbi.nlm.nih.gov/1328848
Autor:
N R, Hartman, G S, Ahluwalia, D A, Cooney, H, Mitsuya, S, Kageyama, A, Fridland, S, Broder, D G, Johns
Publikováno v:
Molecular pharmacology. 40(1)
2',3'-Dideoxyadenosine (ddAdo) and its deamination product 2',3'-dideoxyinosine (ddIno) (didanosine) inhibit the replication and infectivity of the human immunodeficiency virus (HIV) in a number of in vitro assay systems. Early clinical studies (phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::37c30e700b27a30839829f9e41a3d6b8
https://pubmed.ncbi.nlm.nih.gov/1677450
https://pubmed.ncbi.nlm.nih.gov/1677450